ANDA Reviews: Inspector General Weighs In, But Progress Depends On Congress

A report by the HHS Office of Inspector General on FDA's review process for generic drugs illuminates the challenges the agency faces, but reaction to the report underscores the impression that complete resolution of the issue will require Congressional intervention